104 related articles for article (PubMed ID: 38951782)
1. Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival.
Bogyó LZ; Török K; Illés Z; Szilvási A; Székely B; Bohács A; Pipek O; Madurka I; Megyesfalvi Z; Rényi-Vámos F; Döme B; Bogos K; Gieszer B; Bakos E
Respir Res; 2024 Jul; 25(1):262. PubMed ID: 38951782
[TBL] [Abstract][Full Text] [Related]
2. The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.
Shino MY; Zhang Q; Li N; Derhovanessian A; Ramsey A; Saggar R; Britton IN; Amubieya OO; Lari SM; Hickey M; Reed EF; Noble PW; Stripp BR; Fishbein GA; Lynch JP; Ardehali A; Sayah DM; Weigt SS; Belperio JA
Am J Transplant; 2022 Feb; 22(2):565-573. PubMed ID: 34464505
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
4. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
5. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients.
Park JE; Kim CY; Park MS; Song JH; Kim YS; Lee JG; Paik HC; Kim SY
BMC Pulm Med; 2018 Mar; 18(1):45. PubMed ID: 29529999
[TBL] [Abstract][Full Text] [Related]
8. Lung transplantation outcomes after crossing low-level donor specific antibodies without planned augmented immunosuppression.
Courtwright AM; Kamoun M; Diamond JM; Kearns J; Ahya VN; Christie JD; Clausen E; Hadjiliadis D; Patel N; Salgado JC; Cevasco M; Cantu EE; Crespo MM; Bermudez CA
Clin Transplant; 2021 Nov; 35(11):e14447. PubMed ID: 34365656
[TBL] [Abstract][Full Text] [Related]
9. De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome.
Le Pavec J; Suberbielle C; Lamrani L; Feuillet S; Savale L; Dorfmüller P; Stephan F; Mussot S; Mercier O; Fadel E
J Heart Lung Transplant; 2016 Sep; 35(9):1067-77. PubMed ID: 27373824
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients.
Razia D; Hu C; Cherrier L; Nasar A; Walia R; Tokman S
Transpl Immunol; 2022 Dec; 75():101703. PubMed ID: 36049718
[TBL] [Abstract][Full Text] [Related]
11. Impact of donor-specific antibody with low mean fluorescence intensity on allograft outcomes in kidney transplant.
Kitpermkiat R; Kantachuvesiri S; Thotsiri S; Thammanichanond D; Rostaing L; Wiwattanathum P
Transpl Immunol; 2024 Jun; 84():102054. PubMed ID: 38750972
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
[TBL] [Abstract][Full Text] [Related]
13. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
16. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.
Verleden SE; Vanaudenaerde BM; Emonds MP; Van Raemdonck DE; Neyrinck AP; Verleden GM; Vos R
Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146602
[TBL] [Abstract][Full Text] [Related]
17. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
Ziemann M; Altermann W; Angert K; Arns W; Bachmann A; Bakchoul T; Banas B; von Borstel A; Budde K; Ditt V; Einecke G; Eisenberger U; Feldkamp T; Görg S; Guthoff M; Habicht A; Hallensleben M; Heinemann FM; Hessler N; Hugo C; Kaufmann M; Kauke T; Koch M; König IR; Kurschat C; Lehmann C; Marget M; Mühlfeld A; Nitschke M; Pego da Silva L; Quick C; Rahmel A; Rath T; Reinke P; Renders L; Sommer F; Spriewald B; Staeck O; Stippel D; Süsal C; Thiele B; Zecher D; Lachmann N
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1056-1066. PubMed ID: 31213508
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
19. Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation.
Kulkarni HS; Tsui K; Sunder S; Ganninger A; Tague LK; Witt CA; Byers DE; Trulock EP; Nava R; Puri V; Kreisel D; Mohanakumar T; Gelman AE; Hachem RR
Am J Transplant; 2020 Apr; 20(4):1028-1038. PubMed ID: 31677358
[TBL] [Abstract][Full Text] [Related]
20. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
